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Combretastatin A4-Phosphate (CA4P) is a vascular disrupting agent revealing promising results
in cancer treatments for humans. The aim of this study was to investigate the safety and
adverse events of CA4P in healthy dogs as a prerequisite to application of CA4P in dogs with
cancer.
Ten healthy dogs were included. The effects of escalating doses of CA4P on physical, haemato-
logical and biochemical parameters, systolic arterial blood pressure, electrocardiogram, echocar-
diographic variables and general wellbeing were characterised. Three different doses were
tested: 50, 75 and 100 mg m−2.
At all 3 CA4P doses, nausea, abdominal discomfort as well as diarrhoea were observed for several
hours following administration. Likewise, a low-grade neutropenia was observed in all dogs. Doses
of 75 and 100 mg m−2 additionally induced vomiting and elevation of serum cardiac troponine I
levels. At 100 mg m−2, low-grade hypertension and high-grade neurotoxicity were also observed.
In healthy dogs, doses up to 75 mg m−2 seem to be well tolerated. The severity of the neuro-
toxicity observed at 100 mg m−2, although transient, does not invite to use this dose in canine
oncology patients.
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1 | INTRODUCTION
The concepts behind antitumour therapeutics evolved from the con-
ventional direct attack of the proliferating cells to windows of
opportunities that rather influence of the tumour environment.
Greater understanding of the mechanisms by which tumours grow
has led to the identification of more selective oncology targets, such
as the blood vessel support network of the tumour.1,2 Blood flow
inside the tumour is fundamental to guarantee adequate oxygen and
nutrient delivery for continued growth.3,4 Destruction of the existing
tumour vasculature is a promising treatment modality in oncology
patients with solid tumours.5 Vascular disrupting agents (VDA) pro-
duce a rapid shutdown of tumour blood vessels by physical obstruc-
tion of their lumen and the resulting ischemia can lead to extensive
cell death within tumours.6 Combretastatin A4-phosphate,
a microtubule-targeting agent, represents the lead-candidate VDA
that recently (2016) became US FDA-approved in a treatment proto-
col for ovarian cancer in human patients and is currently evaluated in
various Phase II and III clinical trials in combination with chemother-
apy or radiation therapy.7–10
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Because VDA exhibit high specificity for immature tumour vas-
culature, they should not share the side effects observed after con-
ventional cancer therapy, that is, myelosuppression, stomatitis and
alopecia.11–17 In human cancer patients, 52 mg m−2 is the lowest
dose at which tumour blood flow reduction is observed. Adverse
events (AE) observed after CA4P administration are typically mild to
moderate, with nausea and vomiting seen most commonly.13–15
Other AE encountered sporadically in human patients are tumour
pain, cardiovascular toxicity (hypertension) and neurotoxicity. In
2007, Kador and colleagues investigated intravenous administration
of 32 mg m−2 CA4P in dogs as a possible therapy to regress retinal
neovascularisation, and reported low-grade vomiting and loss of
appetite as the only systemic side effects.18 Administration of CA4P
to dogs has not yet been studied for oncologic purposes19; how-
ever, the potential of CA4P in veterinary oncology warrants explora-
tion as also pet dogs with cancer would be candidates for CA4P-
treatment.
This research evaluates the intravenous administration of esca-
lating doses of CA4P in healthy dogs. The aim of this study was to
assess the safety, tolerability and the possible side effects of CA4P
in healthy dogs, and the results will serve as a guide to establish an
acceptable dose to be tested for efficacy in canine patients with
solid cancer.
2 | MATERIAL AND METHODS
2.1 | Preparation of sterile CA4P solutions
Lyophilized CA4P (GMP quality) with a purity of > 99% was pur-
chased from Selleck Chemicals LLC (Houston, Texas) and approval
of the Belgian Federal Agency for Medicines and Health Products
(FAMHP) for the use of CA4P was obtained (approval
no. 0002588).
The drug was accurately weighed and reconstituted in sterile
phosphate buffered saline (PBS) (Thermo Fisher Scientific, Erembode-
gem, Belgium) under sterile conditions in a biological safety cabinet.
A stock solution of CA4P was prepared and diluted to a final concen-
tration of 50, 75 or 100 mg m2 CA4P in 10 mL PBS, based on the
body surface area (BSA) of every dog.
2.2 | Experimental design
Ten healthy Beagles with a mean body weight of 12.5 kg (5.5 kg)
and 7.75 years old (0.75 years) were enrolled into this study
(Table 1). The protocol adhered to the European Communities Coun-
cil Directive (86/609/EEC) and was approved by the local research
ethical committee of the Faculty of Veterinary Medicine (Merelbeke,
Belgium) (approval no. 2014/162). Adequate measures were taken to
minimise pain and discomfort. Dogs were deemed healthy if no rele-
vant abnormalities were found in a pre-treatment screening. This
consisted of a physical and neurological examination, and a complete
echocardiographic examination with additional pulsed-wave tissue
Doppler imaging (PW-TDI), non-invasive Doppler measurements of
the systolic arterial blood pressure (SABP) and electrocardiogram
(ECG). Blood sample analysis included a complete blood count (CBC),
serum biochemistry and cardiac troponine I (cTnI). Three-way radio-
graphs of the thorax and an abdominal ultrasound concluded the pre-
treatment screening.
The dose-escalation strategy was modelled in a 2 + 2 clinical trial
design.20 An intravenous catheter was inserted in the cephalic vein
and the dogs were randomly divided into 5 groups. Each group
received an intravenous infusion of dissolved CA4P (50, 75 or
100 mg m−2). Combretastatin A4-phosphate was administered over a
time span of 30 minutes using a volumetric pump in all groups but
1, in which CA4P was administered over a time span of 120 minutes.
Two dogs (dogs no. 7 and 8) received prophylactic anti-emetic treat-
ment with maropitant (2 mg kg−1 as oral tablets) 6 hours before
CA4P administration and anti-diarrheic treatment with loperamide
(0.08 mg kg−1 as oral tablets) 6 hours before and 2 hours after CA4P
administration.
Physical and neurological examinations were performed hourly
the first 6 hours after injection, every 2 hours the next 18 hours, fol-
lowed by once daily examinations during 10 days. Blood samples
were collected for CBC and biochemistry profile at 1, 3 and 14 days
after CA4P administration.
To assess cardiovascular toxicity, blood pressure measurements
were made using the Doppler method (Parks Medical Electronics Inc,
Aloha, Oregon). Measurements were performed according to the
American College of Veterinary Internal Medicine (ACVIM) consensus
on blood pressure measurement21 and were started 4 days in
advance of CA4P administration to correctly recognise drug-induced
TABLE 1 Dog characteristics and allocation of dogs per dose level of combretastatin A4-phosphate (CA4P)
Dog no. Sex Age (years) Body weight (kg) CA4P dose (mg m−2) Infusion time (min)
1 MN 7.5 15.5 50 30
2 MN 7.5 13.0 50 30
3 FN 8.0 6.5 75 30
4 FN 8.0 8.5 75 30
5 FN 8.5 7.2 100 30
6 MN 7.0 16.0 100 30
7 MN 7.5 18.0 75 30
8 MN 7.5 14.5 75 30
9 FN 7.0 12.5 100 120
10 MN 7.0 17.5 100 120
Abbreviations: FN, Female neutered; MN, male neutered.
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hypertension and to establish a baseline SABP for every dog. After
CA4P administration, SABP measurements were made every 15 min-
utes for the first hour, every hour during the next 5 hours, every
2 hours during the next 18 hours, and every 12 hours for the next
10 days.
During drug administration, ECG was monitored continuously
using a standard 10-lead ECG. For a period of 5 hours following
administration, 3-lead ECG monitoring was performed using a Holter
ECG-recording device (Novacor Vista, Novacor UK Ltd., Swanley,
UK). QT intervals, corrected for changes in heart rate (HR) with the
Van de Water formula,22 were measured and ventricular arrhythmias
were determined. Blood samples for cTnI measurement were taken
at 24 hours, and at 2 and 4 weeks after administration; and conven-
tional echocardiography with additional PW-TDI was repeated 24 h
after administration of CA4P.
Adverse events were recorded and graded using the Veterinary
Cooperative Oncology Group - Common Terminology Criteria for
Adverse Events (VCOG-CTCAE).23
3 | RESULTS
The doses of CA4P studied and the allocation of dogs per dose level are
listed in Table 1. Abridgement of dose levels as a result of dose limiting
toxicities (DLT) did not occur until the level of 100 mg m−2 was
reached. Subsequent re-investigation of the lower dose level (75 mg
m−2) was pursued. Preventive administration of anti-emetic and anti-
diarrheic drugs was successfully implemented in this group. To deter-
mine whether administration of CA4P over a longer time span dimin-
ished or eliminated the occurrence of side effects, 100 mg m−2 CA4P
was administered over a time span of 120 minutes in 1 group; however,
this did not result in either elimination or diminution of the side effects.
Table 2 lists all AEs that were presumably drug-related.
3.1 | Hematologic toxicity
Transient neutropenia (neutrophil count lower than 2950 μL−1) was
the only hematologic toxicity observed, irrespective of the CA4P
dose level. Neutropenia commenced 3 days after injection of CA4P
and resolved spontaneously within 14 days after injection. Grade
1 neutropenia occurred at dose levels of 50, 75 and also at 100 mg
m−2 when administered over 120 minutes, whereas grade 2 neutrope-
nia was observed when 100 mg m−2 was administered over
30 minutes.
3.2 | Gastro-intestinal toxicity
Across all doses and in all individuals, anorexia, diarrhoea, nausea and
loss of appetite were observed, commencing 1 to 2 hours after the
start of injection and resolving spontaneously after 3 to 4 hours. The
severity of anorexia, nausea and diarrhoea appeared to be dose-
dependent (grade 1 at dose levels of 50 and 75 mg m−2, grade 2 at a
dose level of 100 mg m−2). Vomiting (grade 1) was only observed at
dose levels of 75 and 100 mg m−2. Preventive medical treatment
with anti-emetic and anti-diarrheic drugs resulted in the absence of
these AE, whereas reduction of the infusion rate of CA4P did not.
3.3 | Cardiovascular toxicity
All cardiac examinations were performed by a board-certified cardiol-
ogist. Table 3 lists all cardiovascular AE that were observed.
Concerning the SABP, at dose levels of 50 and 75 mg m−2 there
was no significant increase compared to the baseline SABP through-
out the infusion and a period of 24 h post injection. However, at a
dose of 100 mg m−2 all dogs developed significant hypertension
(SABP > 150 mmHg). The increase over baseline varied from 30% to
50%, commenced 2 hours after administration and returned to base-
line values within 24 hours.
ECG recordings showed a mean baseline HR of 111 beats per
minute (BPM) (range: 80-200 BPM) with 9 dogs displaying a physio-
logic respiratory sinus arrhythmia (RSA) and 1 dog with a sinus tachy-
cardia of 200 BPM. During CA4P administration, no significant
changes in HR were seen. The HR in the dog with baseline sinus
tachycardia decreased from 200 BPM to 160 BPM at the start and
80 BPM (with RSA) at the end of injection. One dog with a baseline
HR of 80 BPM (with RSA) showed sinus bradycardia during the injec-
tion (60 BPM during the first minute and 40 BPM at the end of
CA4P administration). No significant changes were observed in the
QTc-interval during administration when compared to baseline
values. Three of 10 dogs had a baseline QTc > 250 ms. All had less
than 10% change of their QTc during injection, except for 1 dog, that
had an 11% increase in QTc.
Overall mean HR during Holter recordings was 104 BPM (range:
42-208 BPM) and recordings were unremarkable in 6 dogs. Four dogs
showed an abnormally high number of ventricular ectopic beats
(VEB) during monitoring. Three of these dogs showed phases of
accelerated idioventricular rhythm (AIVR) and 1 dog showed 2 epi-
sodes of ventricular tachycardia. No other significant arrhythmias
were observed.
Significantly increased serum cTnI concentrations were noted in
6 cases. At baseline, serum cTnI was below the upper limit of 0.06 ng
mL−1 in all dogs. At dose levels of 75 and 100 mg m−2, almost all
dogs developed a mild elevation, irrespective of the CA4P infusion










CTCAE grade 1-2 3-4 1-2 3-4 1-2 3-4
Neutropenia 2 4 4
Hypertension 4
Anorexia 2 4
Diarrhoea 2 2 4




cTnI elevation 2 4
Abbreviations: CTCAE, common terminology criteria for adverse events;
cTnI, cardiac troponine I.
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rate. Serum cTnI levels returned to baseline levels in all dogs within
4 weeks.
Echocardiographic examination after CA4P administration
revealed no significant changes in cardiac dimensions, nor in systolic
or diastolic functional parameters including PW-TDI, compared to
baseline examinations.
3.4 | Neurotoxicity
Three cases of grade 3 ataxia and motor neuron toxicity of the hind
limbs occurred at dose level 100 mg m−2. Dog no. 6 developed ataxia
and lower motor neuron (LMN) toxicity 24 h post-injection. A com-
plete neurological examination performed by a board-certified neurol-
ogist revealed a bilaterally slightly crouched pelvic limb stance and
gait with decreased ability to extend the stifle joints and a mild ataxia,
and bilaterally absent patellar reflexes. Over the following 3 days, the
ataxia did improve but the dog then mainly showed signs of a bilat-
eral femoral neuropathy, presenting as difficulties in rising and sup-
porting weight on the pelvic limbs, with complete inability to extend
the stifle joints. Over the next 11 days, stifle extension and weight
support improved markedly. However, patellar reflexes remained
absent for another 12 weeks. Dogs no. 9 and 10 developed marked
upper motor neuron (UMN) paraparesis and ataxia 20 to 24 hours
post injection. Neurological signs remained stable for the following
24 h, after which dog no. 10 showed decreased patellar reflexes.
After 3 days, both dogs ameliorated to a grade 2 ataxia but the patel-
lar reflexes were now absent bilaterally in dog no. 10. Patellar
reflexes recovered after 4 weeks. In dogs no. 6 and 10, a lumbar
puncture was carried out, serum creatine kinase measured and elec-
tromyography (EMG) of the affected limbs and magnetic resonance
imaging (MRI) of the entire thoracic and lumbar spinal cord were per-
formed, revealing no abnormalities.
4 | DISCUSSION
This is the first report of the administration of CA4P in healthy dogs
to identify possible AE at escalating doses. So far, the optimal dose in
canine cancer patients has not yet been determined, but according to
the manufacturer’s (OXiGENE) guidelines, 100 mg m−2 is the single-
dose maximum tolerated dose (MTD) of CA4P in healthy dogs (results
unpublished). However, the results obtained in this study suggest that
75 mg m−2 is more likely to be the MTD in dogs. At 100 mg m−2,
several high-grade DLT occurred which, although transient, are unac-
ceptable in a clinical setting.
In this study, we initially opted for an infusion schedule of
30 minutes for practical reasons. Infusing over 30 minutes avoided a
high-drug peak plasma concentration of CA4P and continuous ECG
monitoring was tolerated in the minimally restraint dogs. Dowlatti
and colleagues found no demonstrable difference in the toxicity pro-
file of a 10- or a 60-min CA4P-infusion schedule in human oncology
patients.13 Likewise, the results of our research did not demonstrate
definite advantages of a longer infusion schedule in healthy dogs.
Low-grade nausea and diarrhoea developed in all individuals and
at all CA4P doses, vomiting only at dose levels higher than 50 mg
m−2. Gastrointestinal signs are often-observed AE in CA4P-treated
human cancer patients as well, especially at dose levels over
52 mg m−2.13–15 Nausea, vomiting and diarrhoea induced by CA4P
may be attributable to circulatory changes within the small vessels
due to increases in vascular resistance in the gastrointestinal tract,
alterations in intestinal enzyme balance, or via efferent nervous stim-
ulation of the chemoreceptor trigger zone.13,24–26 The most effective
anti-emetics for chemotherapy-induced nausea and vomiting (CINV)
in human patients are the neurokinin-1 (NK-1) receptor antago-
nists.25,26 In dogs, NK-1 receptor antagonists such as maropitant
have also been demonstrated to have superior activity for prevention
and treatment of acute CINV.27–29 In this study, the combination of
this prophylactic anti-emetic and anti-diarrheic treatment proved to
be effective in preventing the gastrointestinal AE in both dogs.
Most appealing for CA4P administration in human clinical trials is
the absence of traditional cytotoxic side effects common to conven-
tional chemotherapeutic strategies, i.e. myelosuppression, stomatitis
and alopecia.13–17,30,31 Indeed, drug-related anaemia, lymphocytope-
nia or thrombocytopenia was not observed; however, a transient
low-grade neutropenia did occur. This finding was not unexpected
since it has previously been described in human patients that
TABLE 3 CA4P-related cardiovascular toxicities















1 50 130 140 8 200 120 40 225 226 0 0 0 0.04 0.01
2 50 130 150 15 120 110 8 243 250 3 6 0 0.05 0.04
3 75 120 130 8 80 100 −25 263 251.5 −4 0 0 0.03 0.17
4 75 125 145 16 120 100 17 246 273.5 11 0 0 0.02 0.03
5 100 140 200 43 80 80 0 234 237 1 65 0 0.03 0.40
6 100 120 180 50 108 90 17 254 239 −6 3795 344 0.02 4.30
7 75 130 150 15 100 80 20 232 239.5 3 478 15 0.02 0.16
8 75 130 145 12 110 110 0 240 239 0 2 0 0.03 0.02
9 100 120 180 50 80 50 38 251 241 4 8 0 0.02 0.19
10 100 150 195 30 110 75 32 242 246 2 556 25 0.01 1.94
Abbreviations: AIVR, accelerated idioventricular rhythm; cTnI, cardiac troponine I; HR, heart rate; SABP, systolic arterial blood pressure; VEB, ventricular
ectopic beats.
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neutropenia can be observed when administering microtubule-
targeting agents such as CA4P.32 in vitro studies have demonstrated
that CA4P is non-toxic to neutrophil granulocytes,33 so the observed
neutropenia does not seem to result from immunosuppression. Stud-
ies revealed that CA4P may induce neutrophil adhesion and migration
through the endothelial cell monolayer due to cellular adhesion mole-
cule (CAM) expression and increased levels of neutrophil-recruiting
cytokines.34,35 A significant response of these cytokines was demon-
strated in both tumour- and non-tumour-bearing mice treated with
CA4P, suggesting non-tumour-specific recruitment of neutro-
phils.33,35 This could explain the mild and transient neutropenia seen
in our (non-tumour-bearing) dogs.
Signs of cardiovascular toxicity after infusion of CA4P observed
in this study are similar to those reported in human medicine, includ-
ing transient hypertension, increased serum cTnI concentration and
electrocardiographic changes.36 The exact mechanisms of CA4P-
related cardiovascular toxicity remain to be elucidated, but some
hypotheses have been suggested.36 A clinically significant increase in
SABP developed only in the 4 dogs receiving a dose of 100 mg m−2.
Compared to what has been described in human cancer patients,13,14
the increase over baseline at this dose was notably higher and the
onset and return to baseline were rather delayed. Although the
increase was substantial, all dogs remained asymptomatic, interven-
tion was not indicated, and SABP returned to baseline value within
24 hours. A CA4P-related increase in systemic vascular resistance
has been suggested to explain the transient hypertension, since
CA4P may cause vasoconstriction not only in tumours, but also in
non-tumour vascular beds.11,13
Substantial increases in serum cTnI levels were observed in
6 dogs; 5 of them also had increased SABP. This increase in cTnI is
therefore likely to be linked to hypertension, as shown in rats.37
Another mechanism suggested in humans is vasospasm of normal
coronary arteries after infusion of CA4P, leading to transient myocar-
dial ischemia.13,36 Recently, it has been shown by Tochinai and col-
leagues that CA4P may cause myocardial lesions in healthy rats, due
to dysfunction of the myocardial microcirculation and possibly a
direct toxic effect on cardiomyocytes.38 Cardiac cTnI was not meas-
ured in the latter study, but if similar cardiac injury would occur in
dogs, it could explain the observed increase in cTnI. Possible cardiac
injury in the current study seems to be transient because follow-up
of the serum cTnI concentrations showed normalisation within
4 weeks after CA4P administration.
The increase in cTnI did not seem to correlate to significant
structural nor functional echocardiographic changes in this study.
Although cases of myocardial stunning have been described, reports
of echocardiographic myocardial dysfunction after CA4P administra-
tion are rare in humans.39
As for electrocardiographic changes in the CA4P-treated dogs,
QTc prolongation did not seem to be clinically relevant. Similarly,
CA4P administration can cause an increase in QTc-interval in humans
that is statistically significant; however, this increase is often clinically
irrelevant.17 A remarkable finding in this study is the presence of a
significant number of VEBs in 4 dogs, 3 of which received 100 mg
m−2 and 1 which received 75 mg m−2. These ventricular arrhythmias
were considered “benign” and consisted mostly of single VPCs and
accelerated idioventricular rhythms, although couplets and triplets
were also present and 1 dog had 2 runs of ventricular tachycardia.
Interestingly, the 2 highest cTnI concentrations were observed in the
dogs with the highest number of VEBs. In humans, it has been pro-
posed that CA4P-related QTc prolongation may exceptionally predis-
pose to ventricular arrhythmia’s.17 Since no significant QTc
prolongation was witnessed, other mechanisms are likely to contrib-
ute to the observed arrhythmias.
A vexing and often dose-limiting AE of the use of microtubule-
targeting agents is the high rate of neuropathy induced by these com-
pounds.40 Chemotherapy-induced peripheral neuropathy (CIPN) is
dose-cumulative and more frequently occurs in patients with pre-
existing neuropathy, usually manifesting itself as a painful and debili-
tating peripheral axonal neuropathy consisting of paraesthesia, paresis
and ataxia, often accompanied with diminished or absent deep tendon
reflexes.41–43 The preferential toxicity of microtubule-targeting agents
for the nervous system is not understood at a mechanistic level but
can be partially explained both by the relative abundance of tubulin in
neurons, and the importance of an intact, functional microtubule cyto-
skeleton for adequate nerve conduction. Chemotherapy-induced
peripheral neuropathy caused by microtubule-targeting agents is usu-
ally reversible after discontinuation of treatment and in general symp-
toms resolve within 3 to 4 months.43
Three completed dose-escalation studies in human cancer
patients reported a range of neurological effects with neuromotor
toxicity mostly taking the form of lower extremity weakness or
ataxia.13–15 These AE were transient, reversible and generally mild at
lower doses, becoming more severe at higher doses. Interestingly, all
these patients received prior platinum therapy,15 which is also known
to induce peripheral neurotoxicity to various degrees.43
The bilateral loss of patellar reflexes after CA4P administration
has never been documented in human CA4P-treated cancer patients
and was a surprising and unexpected finding. A possible explanation
for these clinical signs is the similarity between combretastatines and
colchicine. Combretastatines are structurally related to colchicine and
interact with tubulin at or near the colchicine binding site.44 In human
patients, the long-term use of colchicine has been found to induce
both myopathy and neuropathy,45,46 and 1 case report of a woman
treated with colchicine describes the absence of deep tendon
reflexes in the legs.46 However, the absence of abnormalities in the
cerebrospinal fluid, the EMG and the MRI-images in the dogs makes
the existence of a neuro- or myopathy less likely. More research is
necessary to explain these clinical signs.
5 | CONCLUSION
This study is the first clinical trial conducted with escalating doses of
the vascular targeting agent CA4P in healthy dogs. Although the data
acquired in this study must be viewed with caution because of the
small number of animals studied and because this study did not
include a control or placebo group, the data do suggest that in
healthy dogs, CA4P is well tolerated at doses up to 75 mg m−2. Keep-
ing in mind that 52 mg m−2 is the lowest dose at which changes in
parameters associated with tumour blood flow reduction is seen in
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human cancer patients, and on the basis of the toxicity criteria found
in this research, the dose recommended for treating canine cancer
patients would be 52 to 75 mg m−2. The efficacy of this dose in
canine cancer patients should be the subject of subsequent research.
Based on the results of the current study it is advisable to perform
screening for cardiovascular disease prior to administration of CA4P
as well as to perform follow-up after treatment, using blood pressure
measurement, cTnI concentration, ECG monitoring and possibly ech-
ocardiography. Preventive treatment for gastrointestinal side effects
is recommended.
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